Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Srijana Baniya

Nurse Practitioner Waco, TX Nurse Practitioner

NPI 1205349933 CMS profile 11006901

611 W Hwy 6 Ste 101, Waco, TX 76710

Open in the dashboard

General payments

$6,871

234 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Srijana Baniya of Waco, TX is reported in the CMS Open Payments database as having received $6,871 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,542 111
2024 General $1,391 56
2023 General $1,674 38
2022 General $1,213 28
2021 General $50 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srijana Baniya
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Srijana Baniya were reported at $2,542. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Srijana Baniya Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $50 $135 $40–$426 $132
2022 $1,213 $152 $48–$470 $149
2023 $1,674 $166 $54–$529 $160
2024 $1,391 $173 $55–$556 $164
2025 $2,542 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,248 24 payments
  2. Amgen Inc. $849 35 payments
  3. Relievant Medsystems, Inc. $630 7 payments
  4. AbbVie, Inc. $594 30 payments
  5. Spinal Simplicity, LLC $456 10 payments
  6. Janssen Biotech, Inc. $416 13 payments
  7. Novartis Pharmaceuticals Corporation $350 13 payments
  8. E.R. Squibb & Sons, L.L.C. $272 9 payments
  9. AstraZeneca Pharmaceuticals LP $262 11 payments
  10. Mallinckrodt Hospital Products Inc. $238 8 payments
  11. Other $1,554 74 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,106 228 payments
  2. Travel and Lodging $566 3 payments
  3. Education $199 3 payments
Products named General payments · program years 2021–2025
  1. Intracept Pain $580 6 payments
  2. HA MINUTEMAN G3-R $456 10 payments
  3. PROCLAIM Neuromodulation $445 11 payments
  4. Intracept Pain $443 3 payments
  5. TREMFYA $416 13 payments
  6. ENSITE PRECISION $367 3 payments
  7. COSENTYX $350 13 payments
  8. KRYSTEXXA $344 13 payments
  9. PROCLAIM Neuromodulation $284 3 payments
  10. ORENCIA $272 9 payments
  11. Other $3,896 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record